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ABSTRACT
Worldwide, colorectal cancer (CRC) is the third
most frequently diagnosed cancer in men and
the second in women. Metastatic disease
develops in more than half of the patients and
carries a poor prognosis. Over the past three
decades, significant advances have been made in
the treatment of metastatic colorectal cancer
(mCRC). The development of new cytotoxic
agents and the incorporation of target-specific
agents in first-, second-, third-, and nowadays
even fourth-line treatment has prolonged
median overall survival up to 24–28 months.
However, 5-year survival rates remain
disappointingly low. This review summarizes
the currently available cytotoxic treatment
options for mCRC, and highlights the further
emerging role of vascular endothelial growth
factor (VEGF)-inhibiting strategies, emphasizing
the role of aflibercept. Aflibercept is a
recombinant fusion protein with high VEGF
affinity, and is the second antiangiogenic agent
to obtain registration in the treatment of mCRC.
Keywords: Aflibercept; Cytotoxic therapy;
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INTRODUCTION
Worldwide, colorectal cancer (CRC) is the third
most prevalent cancer in men and the second in
women. Globally, CRC has an estimated yearly
incidence of more than 1.2 million and an
annual mortality of over 600,000 [1]. Metastatic
disease develops in 50 % of patients and carries
an ultimately fatal prognosis, with 5-year
survival rates of only 10 % [2].
Over the past three decades, significant
progression has been made in the treatment of
metastatic colorectal cancer (mCRC). Cytotoxic
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chemotherapy has changed from single-agent
intravenous (i.v.) bolus 5-fluorouracil (5-FU) to
a plethora of regimens containing 5-FU/
capecitabine, irinotecan, and/or oxaliplatin. In
addition to these cytotoxic chemotherapies, the
development and integration of so-called
target-specific agents into the treatment of
mCRC has further initiated a change in
treatment paradigms and has profoundly
shifted expectations in patients. By carefully
selecting patients and combining and/or
sequencing the currently available treatment
options, median overall survival (OS) for mCRC
patients has gradually increased from a median
of 6 months to a median that is currently
24–28 months [3].
Unfortunately, however, until now no major
gains have been made in 5-year survival rates
and the number of patients cured from mCRC
still remains disappointingly low.
Target-specific agents that have found their
way into the treatment of mCRC can be divided
into agents targeting the tumoral epidermal
growth factor receptor (EGFR), and those
targeting the vascular endothelial growth
factor (VEGF) and its receptors (VEGFR)
expressed on endothelial cells. In this review,
the authors will not discuss EGFR inhibition
strategies, but will focus on the role of VEGF
inhibition.
The need for new and more active
antiangiogenic agents in the treatment of
mCRC is felt by many. Despite great promises
observed in preclinical models, and interesting
hints of biological and clinical activity observed
in early clinical studies performed over a period
of almost four decades, it seems fair to state that
the overall added value of angiogenesis
inhibition in the treatment of mCRC is
modest at best. Studies combining first- and
second-line cytotoxic treatment with VEGFR
tyrosine kinase inhibitors have almost
invariably yielded negative results, with no
significant effects on progression-free survival
(PFS) and OS [4, 5]. Combining first-
and second-line cytotoxic treatment with
bevacizumab has demonstrated improvements
in PFS, but only a few studies have been
published that demonstrated effects on OS
[6, 7].
Recently, however, three studies have been
published demonstrating the effects of
angiogenesis inhibition on OS, and the
publication of two of these studies has boosted
recent US Food and Drug Administration (FDA)
registration of regorafenib and aflibercept
[8–10]. This landmarked the second and third
registration of an antiangiogenic agent in the
treatment of mCRC after the first registration of
such an agent took place almost a decade ago.
The Treatment across Multiple Lines (TML)
trial provided statistical evidence that
continuing bevacizumab treatment beyond
tumor progression (while changing the
chemotherapy schedule) improves OS [8]. The
CORRECT trial showed that regorafenib, which
is a broad-spectrum tyrosine kinase inhibitor
with antiangiogenic activity, was also
associated with a statistical improvement in
OS in patients with mCRC who progressed after
all standard treatment options [9]. Finally, the
VELOUR trial demonstrated a statistically
significant improvement in OS in patients
when given second-line treatment with
infusional 5-FU/leucovorin and irinotecan
(FOLFIRI) and aflibercept [10].
After a brief summary of the currently
available cytotoxic treatment options for
mCRC and the role of bevacizumab within
these options, this review describes the
structure and function of aflibercept, and
highlights the results of early clinical studies.
After discussing the final results of the VELOUR
study and the impact of treating mCRC with
26 Biol Ther (2013) 3:25–33
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VEGF inhibitors beyond progression, a brief
discussion about the role of aflibercept within
mCRC treatment is given.
METHODS
A systematic literature search was conducted
using PubMed with no limitations of language
or years of publication. The following keywords
were used: ‘‘metastatic colorectal cancer,’’
‘‘aflibercept,’’ ‘‘bevacizumab,’’ ‘‘cytotoxic
therapy,’’ and ‘‘vascular endothelial growth
factor.’’ Additionally, the authors reviewed
abstracts related to aflibercept from major
congresses in North America and Europe over




As mentioned previously, fluoropyrimidines
have for decades been the backbone of
systemic treatment of mCRC. 5-FU functions
as a nucleoside analog, preventing DNA
replication, and leucovorin potentiates its
effect [11]. Capecitabine is the oral prodrug of
5-FU and has demonstrated efficacy at least
similar to that of i.v. bolus 5-FU [12, 13].
Irinotecan, a topoisomerase I inhibitor, was
initially approved for second-line treatment of
mCRC in 1998 based upon results from two
randomized trials demonstrating an
improvement in both PFS and OS when
compared to best supportive care or 5-FU/
leucovorin in patients with mCRC refractory
to 5-FU [14, 15]. Nowadays, irinotecan
containing combination schedules are
considered an essential part of standard first-
and second-line treatments of mCRC.
Oxaliplatin, a platinum derivative, formed
another milestone in mCRC treatment. Two
randomized trials evaluated the addition of
oxaliplatin to a regimen of 5-FU/leucovorin in
first-line therapy for mCRC. The results showed
a higher response rate, increased PFS, but had
no significant effect on OS [16, 17]. A phase 3
trial demonstrated efficacy of oxaliplatin in
addition to 5-FU/leucovorin as second-line
therapy for mCRC [18]. In 2002, these data led
to the approval of oxaliplatin for treatment in
mCRC, and since then oxaliplatin is considered
another essential part of treatment strategies in
this disease [19].
Numerous different combinations of i.v. or
oral 5-FU with irinotecan and/or oxaliplatin in
schedules, such as infusional 5-FU/leucovorin
and oxaliplatin (FOLFOX), capecitabine
and oxaliplatin (CAPOX/XELOX), FOLFIRI, and
infusional 5-FU/leucovorin, oxaliplatin, and
irinotecan (FOLFOXIRI), have convincingly
shown their effectiveness in first- and/or
second-line treatment settings of mCRC [20].
Although upfront combination therapy is
frequently used, especially in patients with
symptomatic disease or in patients in whom a
response is required to open possibilities for
additional treatment, such as surgery, exposure
to all mentioned cytotoxic drugs throughout
the sequential lines of treatment of mCRC
appears to be as justifiable as a specific




Bevacizumab is a humanized monoclonal
antibody that binds to VEGF. Bevacizumab
prevents binding of circulating VEGF-A to
specific endothelial VEGFRs, which results in
the inhibition of VEGF signalling and
angiogenesis [22].
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In first-line treatment of mCRC,
bevacizumab has not demonstrated single-
agent activity, but when combined with
various chemotherapy regimens, bevacizumab
almost invariably increases response rates and
PFS [23]. Of note, bevacizumab showed impact
on OS in only one randomized study, which
used the 5-FU/leucovorin and irinotecan (IFL)
regimen containing bolus 5-FU and irinotecan
administration as a backbone [6]. This IFL
schedule is generally considered to be less
active than infusional 5-FU schedules.
In second-line treatment of mCRC, the
E3200 study demonstrated improvement in OS
of bevacizumab when combined with FOLFOX
[7]. In this study, bevacizumab was dosed at
10 mg/kg every 14 days.
These two trials led to the FDA approval of
bevacizumab in 2004 for first-line (and, in 2006,
for second-line) treatment of mCRC when
combined with 5-FU-containing regimens.
In addition to these randomized trials,
the observational Bevacizumab Regimens:
Investigation of Treatment (BRiTE) and
Avastin Registry: Investigation of Efficacy and
Safety (ARIES) studies suggest that the use
of bevacizumab could be effective after
progression in first-line mCRC treatment
[24, 25]. In a multivariate analysis, the
sustained inhibition of angiogenesis was found
to be associated with improved survival.
However, findings from observational studies
may be prone to bias and, therefore, should be
interpreted with great caution.
The recently published TML study is the first
prospective randomized trial evaluating the role
of continuing bevacizumab as part of second-
line treatment for patients with mCRC who
progressed after first-line bevacizumab-
containing therapy [8]. In this trial, 820
patients who had received first-line
bevacizumab-containing chemotherapy were
randomized to receive second-line
chemotherapy with alternate cytotoxics with
or without bevacizumab. The primary endpoint
of this study was OS, and the secondary
endpoint was PFS. Median OS was 11.2 months
for chemotherapy plus bevacizumab and
9.8 months for chemotherapy alone [hazard
ratio (HR) 0.81; 95 % confidence interval (CI)
0.69–0.94; P = 0.0062]. Median PFS was
5.7 months and 4.1 months, respectively (HR
0.68; 95 % CI 0.59–0.78; P\0.0001). These
results were regardless of whether oxaliplatin
or irinotecan had been part of the second-line
treatment.
A second phase 3 clinical trial with a similar
design stopped accrual when results of the
TML study were released [26]. Results from
this study, however, also showed that the
continuation of bevacizumab beyond
progression in patients with mCRC resulted in
a significant benefit in PFS.
ANTIANGIOGENIC AGENTS
IN mCRC: AFLIBERCEPT
Aflibercept (formerly known as VEGF-trap or
AVE0005) is a novel human recombinant
protein which is constructed by fusing the
second extracellular domain of VEGFR-1 and
the third extracellular domain of VEGFR-2 to
the Fc segment of immunoglobulin G1. It
functions as a soluble, high-affinity decoy
receptor preventing VEGF-A, VEGF-B, and
placental growth factor (PlGF) from interacting
with their cognate receptors [27]. In contrast to
bevacizumab, aflibercept not only targets VEGF-
A, but also VEGF-B and PlGF, forming a
pharmacologic blockade of the VEGF pathway.
Preclinical studies in various tumor models
have demonstrated reduction of tumor
vasculature and size, and inhibition of ascites
formation [28].
28 Biol Ther (2013) 3:25–33
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Clinical Trials with Aflibercept
Phase 1
Completed phase 1 trials suggest that single-
agent aflibercept is well tolerated. The
first phase I study evaluated safety,
pharmacokinetics, and pharmacodynamics of
i.v.-administered aflibercept in 47 patients with
a variety of refractory solid tumors and non-
Hodgkin’s lymphoma [29]. The most common
adverse events were fatigue, nausea, and
vomiting, and their frequency was not
dose-dependent. Toxicities associated with
aflibercept included dysphonia, hypertension,
and proteinuria. Dose-limiting toxicities were
rectal ulceration and proteinuria at the 7.0 mg/
kg dose. The recommended dose was set at
4 mg/kg i.v. every 2 weeks [29].
A dose-escalation study of subcutaneous-
administered aflibercept in 38 patients with
advanced solid tumors revealed proteinuria,
fatigue, injection-site reaction, nausea,
myalgia, anorexia, hypertension, and
hoarseness as the most frequently occurring
side effects [30]. Grade 3/4 hypertension and
proteinuria occurred in 8 and 3 % of patients,
respectively, and was reversible. Due to
solubility and dosing limits with the
subcutaneous formulation, the maximum
tolerated dose could not be determined.
In a phase 1 dose-escalation study of i.v.
aflibercept in combination with irinotecan,
infusional 5-FU, and leucovorin (LV5FU2) in
38 patients with advanced solid tumors, the
recommended dose of aflibercept could also be
set at 4 mg/kg i.v. every 2 weeks [31]. The most
common grade 3/4 adverse events with the
4 mg/kg dose were neutropenia, hypertension,
fatigue, and diarrhea. Antitumor activity was
assessed in 10 evaluable patients receiving
aflibercept at the 4 mg/kg dose. Five patients
had partial responses (three colorectal cancer,
one pancreatic cancer, one synovial carcinoma)
and five patients had stable disease lasting more
than 3 months [31].
Phase 2
A multicenter, open-label, phase 2 clinical trial
investigated aflibercept in patients with
previously treated mCRC [32]. In total, 75
patients were enrolled in two cohorts,
bevacizumab naı¨ve (n = 24) or bevacizumab
treated (n = 51). Single-agent aflibercept was
given at the dose of 4 mg/kg i.v. every 2 weeks.
In the bevacizumab-naı¨ve cohort, the best
response was stable disease for 16 weeks or
more in five patients. In the prior
bevacizumab cohort, one patient achieved a
partial response and six patients had stable
disease for 16 weeks or more. The median PFS in
the bevacizumab-naı¨ve and prior bevacizumab
cohorts was 2.0 months (95 % CI
1.7–8.6 months) and 2.4 months (95 % CI
1.9–3.7 months), respectively. The most
common grade 3 or higher treatment-related
adverse events were hypertension, proteinuria,
fatigue, and headache. It was concluded that
aflibercept was well tolerated and had limited
single-agent activity in pretreated mCRC,
regardless of prior therapy with bevacizumab.
The AFFIRM trial is a randomized phase 2
study investigating aflibercept combined with
modified FOLFOX6 (infusional 5-FU/leucovorin
and oxaliplatin) in first-line treatment of mCRC
[33]. The primary endpoint of this study was PFS
rate at 12 months. The secondary outcome
measures included overall response rate, PFS,
and OS. Preliminary results show no significant
difference in PFS at 1 year.
Phase 3
The phase 3 VELOUR trial was a randomized,
placebo-controlled study evaluating the
combination of aflibercept plus FOLFIRI in the
Biol Ther (2013) 3:25–33 29
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second-line treatment of mCRC after
oxaliplatin failure [10]. In this trial 1,226
patients were randomly assigned to receive
either aflibercept (4 mg/kg i.v.; 612 patients)
or placebo (614 patients) every 2 weeks in
combination with FOLFIRI. Approximately one
third of these patients had previously been
treated with bevacizumab. Addition of
aflibercept to FOLFIRI significantly improved
OS from 12.06 months to 13.50 months,
respectively (HR 0.817; 95.34 % CI
0.713–0.937; P = 0.0032). Aflibercept also
significantly improved PFS and response rate.
Median PFS was 6.90 months in the aflibercept
arm and 4.67 months in the control arm (HR
0.758; 95 % CI 0.661–0.869; P\0.0001).
Response rate was 19.8 % (95 % CI
16.4–23.2 %) with aflibercept plus FOLFIRI
versus 11.1 % (95 % CI 8.5–13.8 %) with
placebo plus FOLFIRI (P = 0.0001). Grade 3
and 4 adverse events with at least a 2 % higher
incidence in the aflibercept arm versus placebo
were diarrhea, asthenic conditions, stomatitis
and ulceration, infections, hypertension,
gastrointestinal and abdominal pain,
neutropenia and neutropenic complications,
and proteinuria. Adverse events leading to
treatment discontinuation occurred in 26.8 %
of patients receiving aflibercept plus FOLFIRI
and 12.1 % of patients receiving placebo plus
FOLFIRI. The adverse events leading most
frequently to permanent discontinuation were
asthenic conditions, infections, diarrhea, and
hypertension. Compared with the TML study
and the AVastin IRInotecan (AVIRI) study
(bevacizumab plus FOLFIRI in first-line mCRC
[34]), the VELOUR trial demonstrated a similar
toxicity profile. In the VELOUR trial, a
prespecified subgroup analysis demonstrated
no significant interaction of prior bevacizumab
therapy on PFS and OS in both treatment arms.
These results suggest that aflibercept is effective
for patients with mCRC who progressed after
first-line bevacizumab-containing therapy.
In the near future, a randomized study of
aflibercept is planned for patients with mCRC
who have received perioperative FOLFOX
chemotherapy and have subsequently
undergone complete resection or ablation of
metastatic disease [35].
CONCLUSION
In 2012, aflibercept obtained FDA approval for
the second-line treatment of mCRC in
combination with FOLFIRI chemotherapy. The
approval of a second antiangiogenic agent for
this indication is an important milestone in the
treatment of this disease. Aflibercept has a
powerful biologic profile, targeting VEGF-A,
VEGF-B, and PlGF, and the pivotal VELOUR
study provided compelling evidence that
aflibercept improves OS in second-line mCRC,
which, so far, is an almost unique feature [10].
Last year, more relevant results were
published in the setting of mCRC treatment,
as in addition to the VELOUR data, the
TML study demonstrated that bevacizumab
continuation beyond progression of first-line
mCRC treatment also yielded prolongation of
OS [8]. When taking a close look at the data of
these two landmark trials, realizing that a
formal head-to-head comparison cannot be
made, the similarity between the data is
striking. Both studies show a 1.4-month
benefit in OS, whereas the toxicity profile of
bevacizumab and aflibercept shows an almost
complete overlap. Another conclusion from
this, and again emphasizing the indirect
comparison between these studies, is that
most likely the sequence of first- and second-
line chemotherapy does not seem to be very
distinctive in determining the clinical endpoint
of survival.
30 Biol Ther (2013) 3:25–33
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Whereas bevacizumab has demonstrated
activity in various studies of first-line
treatment of mCRC, at this moment only
preliminary data from a randomized phase 2
(AFFIRM) trial combining aflibercept with
modified FOLFOX in first-line mCRC are
available. Therefore, making any comparisons
regarding the activity of these two agents in
first-line treatment of mCRC is, at best,
currently speculative.
Given the seemingly comparable efficacy of
bevacizumab and aflibercept in mCRC, it is
highly questionable, in the authors’ view,
whether a direct comparison between these
two antiangiogenic agents combined with
chemotherapy within the context of a large
randomized, noninferiority study in first-line
treatment will ever be pursued.
The promising results with aflibercept
demonstrate that the concept of
antiangiogenesis inhibition remains a valuable
area of investigation, even years after the
registration of bevacizumab. This new drug
represents an important addition to the
armamentarium of mCRC treatment.
However, and to put the data into a critical
perspective, current antiangiogenic therapies
are effective to only a limited degree in a
small, poorly-predictable subset of patients
with mCRC.
Additional studies, therefore, will be
necessary to determine the exact role of
aflibercept in various subsets of patients, and
hopefully these future trials will reveal optimal
combinations with all agents currently
available. This clinical research will have
to be focussed on the recognition and/or
development of biomarkers that may help to
select those patients most likely to benefit from
angiogenesis inhibition. Reliable markers can
then predict the response and ultimately
prognosis of patients, and will as such provide
the foundation for an optimally individualized/
personalized treatment of mCRC.
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